Switzerland

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.

Programme implementation concluded on March 31, 2026, with the global initiative on track to exceed its target of reaching at least 21 million under-immunised children.

Opioids bear responsibility for the largest portion of drug-related deaths globally, accounting for roughly 450,000 of the approximate 600,000 annual deaths linked to drug use.

This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.

Amplifai Health’s acceptance into this programme validates the company’s approach to implementing AI technology in practical healthcare settings where it can make an immediate difference in patient care.

The initiative supports the World Bank Group’s ambitious goal of delivering quality health services to 1.5 billion people by 2030.

Measles cases have increased globally, with an estimated 11 million infections in 2024—about 800,000 more than pre-pandemic levels in 2019.

The deal promises to generate up to USD90 million in savings for Gavi and participating countries over the next five years.